ClinicalTrials.gg
CompletedNCT06084104Updated Dec 18, 2024

DZD9008 PK Study in Hepatic Impairment Subjects

A Phase 1 interventional study of DZD9008 and DZD9008 in Hepatic Impairment, sponsored by Dizal Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-18.

Sponsored by Dizal Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study will investigate the pharmacokinetics, safety, and tolerability of DZD9008 in subjects with hepatic impairment compared to subjects with normal hepatic function

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Dizal Pharmaceuticals is the lead sponsor of 39 studies on the registry; 15 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject is male or female 18 to 75 years of age, inclusive, at screening.
  2. The subject has a of 18.0 to 40.0 kg/m2, inclusive, at screening and check-in.
  3. The subject has a minimum body weight of 50.0 kg, at screening and check-in.
  4. The subject has a resting pulse rate of ≥ 40 and \< 100 beats per minute with no deviation as judged by the investigator.
  5. The subject agrees to comply with all protocol requirements.
  6. The subject is able to provide written .

    Additional Inclusion Criteria for Healthy Subjects Only (Cohort 2) Only (7-11):

  7. The subject has normal hepatic function. No known or suspected hepatic impairment based on liver function tests (e.g., , AST, ALP, and ), albumin, and is defined as the following with a single repeat permitted to assess eligibility if needed, at screening and check-in:

    1. ALT and AST ≤
    2. Total bilirubin ≤ ULN (subjects with a history of Gilbert syndrome are eligible if they only have elevated total bilirubin)
    3. ALP ≤ ULN
    4. Albumin ≥ 3.6 g/dL
    5. Prothrombin time ≤ ULN
  8. The subject has a resting blood pressure of 90 to 145 mmHg (systolic) and 40 to 95 mmHg (diastolic), at screening and check-in.
  9. The subject has a of ≤ 450 msec, at screening and check-in.
  10. The subject is judged by the investigator to be in good general health, as determined by medical history, clinical laboratory assessments, vital sign measurements, 12 lead results, and physical examination findings.
  11. Each subject with normal hepatic function (Cohort 2) must individually match a subject with impaired hepatic function (Cohort 1) by age (± 10 years), body weight (± 10 kg), and sex (similar distribution of males and females).

    Additional Inclusion Criteria for Subjects with Hepatic Impairment (Cohort 1) Only (12-18):

  12. The subject satisfies the Class B of the classification (no albumin use within 14 days). Six out of 10 subjects also meet NCI ODWG Group C criteria.
  13. The subject has a diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary to any acute ongoing hepatocellular process), with features of cirrhosis due to any etiology, except for DILI, which is confirmed by at least one of the following criteria:

    1. histologically by prior liver showing cirrhosis
    2. clinically by physical examination, laboratory data, liver imaging, or endoscopic findings
  14. The subject has following clinical laboratory values, at screening and check-in:

    1. ALT and AST ≤ 5 × ULN
    2. Total bilirubin ≤ 3 × ULN
    3. ≥ 1.5 × 109/L
    4. count ≥ 30 × 109/L
    5. ≥ 90 g/L
  15. The subject has chronic (more than 6 months) and stable hepatic impairment (ie, no acute episodes of illness within 30 days before screening due to deterioration of hepatic function) as assessed by the NCI-ODWG criteria (Group C) or a Child-Pugh classification score of moderate (7 to 9 points).
  16. The subject has a resting blood pressure of 90 to 155 mmHg (systolic) and 50 to 100 mmHg (diastolic), at screening and check-in.
  17. The subject has a QTcF of ≤ 470 msec, at screening and check-in.
  18. The subject is judged by the investigator to be in good general health, as determined by medical history, clinical laboratory assessments, vital sign measurements, 12 lead ECG results, and physical examination findings, except for findings that, as judged by the investigator, are consistent with the subject's hepatic impairment or other stable concomitant medical conditions.

Exclusion criteria

Exclusion criteria:

  1. The subject has a history or clinical manifestations of a significant neurological, renal, cardiovascular, gastrointestinal, pulmonary, hematologic, immunologic, or psychiatric disease that would preclude study participation, as judged by the investigator.
  2. The subject has any surgical or medical condition that may alter the absorption, distribution, metabolism, or excretion of drugs (e.g., gastrectomy).
  3. The subject has a history of cancer () with the following exceptions:

    1. adequately treated nonmelanoma skin cancer or carcinoma in situ of the cervix, or
    2. other malignancies which have been successfully treated with appropriate follow up and therefore unlikely to recur for the duration of the study
  4. The subject has a history of being or has a positive test result for types 1 or 2 antibodies at screening.
  5. The subject has an acute or chronic infection requiring treatment with oral antibiotics (except, rifaximin for the treatment of hepatic encephalopathy), antivirals, antiparasitic, antiprotozoals, or antifungals within 4 weeks prior to Day 1 or superficial skin infection within 1 week prior to Day 1.
  6. The subject has a history of risk factors for Torsades de Pointes (e.g., heart failure/cardiomyopathy or family history of long syndrome), has hypokalemia or hypomagnesemia, and is taking concomitant medications that prolong the QT/QTc interval.
  7. The subject has uncontrolled hypertension despite optimal medical management.
  8. The subject had arterial or venous thrombotic or embolic events such as cerebrovascular accident (including ), deep vein thrombosis or pulmonary embolism within 6 months before the start of study drug administration.
  9. The subject tests positive for breath alcohol test at screening and on check-in (Day 1).
  10. The subject is unable or unwilling to restrict smoking to 5 cigarettes or less per day.
  11. The subject is involved in strenuous activity or contact sports within 24 hours of the first dose of study drug or during the study.
  12. The subject has donated blood (excluding plasma donation) of ≥ 500 mL within 60 days before the first dose of study drug.
  13. The subject has poor peripheral venous access.
  14. The subject should not be any of the following:

    1. investigator staff member or their family members
    2. site staff member otherwise supervised by the investigator, or employees, including their family members, directly involved in the conduct of the study
  15. The subject has a history of relevant drug and/or food allergies (ie, allergy to DZD9008 or any , or any significant food allergy).
  16. The subject has received DZD9008 or any other drug in another investigational study within 30 days of dosing.
  17. The subject is enrolled in another clinical study or has used any investigational drug or device within 4 weeks (or 5 times the half-life of the pervious drug [if known], whichever is longer), prior to dosing with study drug. The window will be derived from the date of the last dose of study drug in the previous study.
  18. The subject has used a strong or moderate inhibitor or inducer of and/or P gp including St. John's Wort, within 14 days and 28 days, respectively, prior to dosing and until the completion of the last PK sample collection unless it is deemed acceptable following consultation with Dizal Pharma's medical monitor and the investigator.
  19. The subject has used PPIs within 5 days prior to dosing until 24 hours after dosing. Use of H2-antagonists and antacids within 12 hours prior to dosing until 12 hours after dosing unless it is deemed acceptable following consultation with Dizal Pharma's medical monitor and the investigator.
  20. In the opinion of the investigator, the subject is not suitable for entry into the study.

    Additional Exclusion Criteria for Healthy Subjects Only (Cohort 2):

  21. The subject with normal hepatic function has any of the following:

    1. evidence or history of bleeding diathesis, or
    2. any hemorrhage or moderate bleeding event within 4 weeks of start of study drug administration
  22. The subject has a positive result for or Ab.
  23. The subject has an estimated (CKD-EPI formula or method) of \< 90 mL/min.
  24. The subject has used any vaccine or used any prescription (excluding hormonal and hormone replacement therapy) or over the counter medications (except paracetamol [up to 2 g per day]), including herbal or nutritional supplements, within 14 days before the first dose of study drug and throughout the study.
  25. The subject has a positive test result for drugs of abuse or alcohol at screening or before the first dose of study drug.

    Additional Exclusion Criteria for Subjects with Hepatic Impairment Only (Cohort 1):

  26. The subject has fluctuating or rapidly deteriorating hepatic function, as indicated by recent history or worsening of clinical (ie, abdominal pain, nausea, vomiting, anorexia, or fever) and/or laboratory signs of hepatic impairment, as judged by the investigator.
  27. The subject has evidence of acute viral hepatitis within 30 days before dosing with study drug.
  28. The subject has an active hepatitis B or C viral infection.
  29. The subject has history or symptoms of hepatic encephalopathy Grade 2 or above within 3 months prior to screening visit.
  30. The subject has a history of unstable diabetes mellitus as evidenced by ≥ 9% at screening.
  31. In the opinion of the investigator, the subject has clinically demonstrable severe ascites and/or pleural effusion.
  32. The subject has evidence of hepatopulmonary syndrome, hydrothorax, or hepatorenal syndrome.
  33. The subject had an organ transplant or is on a waiting list.
  34. The subject had a portosystemic shunt (including transjugular intrahepatic portosystemic shunts).
  35. The subject has an estimated glomerular filtration rate (CKD-EPI formula) of \< 60 mL/min.
  36. The subject has symptoms consistent with spontaneous bacterial peritonitis, known active spontaneous bacterial peritonitis, or a history of spontaneous peritonitis within the last 6 months.
  37. The subject is suspected of having hepatocellular carcinoma (ie, if α fetoprotein > 50 ng/mL at screening), subjects will undergo appropriate diagnostic studies (e.g., CT scan or hepatic ultrasound) to exclude the possibility of hepatocellular carcinoma.
  38. The subject has received any vaccine or used any prescription (excluding hormonal birth control and hormone replacement therapy) or over the counter medications, including herbal or nutritional supplements, within 14 days before the first dose of study drug and throughout the study, except those essential for the management of hepatic impairment or the treatment of stable concomitant medical conditions, as judged by the investigator. The dose of an approved medication must remain stable from 7 days before study drug dosing and throughout the study.
  39. The subject has a positive test result for drugs of abuse (except positive test results associated with prescription medications that have been reviewed and approved by the investigator) or alcohol at screening or prior to study drug dosing.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Hepatic impairment

    Subjects with hepatic impairment

    Drug: DZD9008

  • Experimental
    Healthy Subject

    Subjects with normal hepatic function

    Drug: DZD9008

Interventions

  • A single oral dose of 200mg DZD9008

  • A single oral dose of 200mg DZD9008

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma (peak) drug concentration [Cmax]

    Time frame: Day 1 to day 14

  2. Area under plasma concentration time curve from zero to infinity (AUCinf)

    Time frame: Day 1 to day 14

  3. Area under the plasma concentration-curve from time zero to last quantifiable concentration (AUClast)

    Time frame: Day 1 to day 14

Secondary outcomes

  1. Apparent total body clearance (CL/F)

    Time frame: Day 1 to day 14

  2. Area under plasma concentration time curve from zero to infinity (AUCinf)

    Time frame: Day 1 to day 14

  3. Terminal phase half-life (t1/2),

    Time frame: Day 1 to day 14

  4. Time to maximum observed plasma concentration (Tmax)

    Time frame: Day 1 to day 14

  5. Fraction unbound (Fu)

    Time frame: Day 1 to day 14

  6. Unbound area under plasma concentration time curve from zero to infinity (AUC0-inf, u)

    Time frame: Day 1 to day 14

  7. Unbound area under the plasma concentration-curve from time zero to last quantifiable concentration (AUC0-last, u)

    Time frame: Day 1 to day 14

  8. Unbound maximum observed plasma (peak) drug concentration (Cmax, u)

    Time frame: Day 1 to day 14

  9. Unbound apparent total body clearance (CLu/F)

    Time frame: Day 1 to day 14

  10. Unbound apparent volume of distribution (Vz,u/F)

    Time frame: Day 1 to day 14

  11. Adverse events

    Time frame: Day 1 to day 14

  12. Clinical laboratory test results: hematology, coagulation, serum chemistry, urinalysis

    Time frame: Day 1 to day 14

  13. 12-lead ECG results: tracings, rhythm, RR interval, PR interval, QRS width, QT interval, and QTcF

    Time frame: Day 1 to day 14

  14. Vital sign measurements: systolic and diastolic blood pressure, pulse rate, respiratory rate and body temperature

    Time frame: Day 1 to day 14

  15. Physical examination findings: assessment of skin, head, ears, eyes, nose, throat, neck, thyroid, lungs, heart, cardiovascular, abdomen, lymph nodes, and musculoskeletal system/extremities

    Time frame: Day 1 to day 14

07

Study locations

2 sites
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • American Research Corporation
    San Antonio, Texas 78215, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Jun 2024, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2023
First posted
Oct 16, 2023
StartActual
Oct 17, 2023
Primary completionActual
Jun 12, 2024
CompletionActual
Oct 23, 2024
Last update
Dec 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06084104
Collaborators
PPD Development, L.P.
Responsible party
Sponsor
First posted
Oct 16, 2023
Start date
Oct 17, 2023
Primary completion
Jun 12, 2024
Completion
Oct 23, 2024
Last update
Dec 18, 2024

Study contacts

Thomas C Marbury, MD
principal investigator · Orlando Clinical Research Center
Eric Lawitz, MD
principal investigator · Texas Liver Institute

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sunvozertinib

Start the discussion